<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950245</url>
  </required_header>
  <id_info>
    <org_study_id>MH-INKA-BAR-19</org_study_id>
    <nct_id>NCT03950245</nct_id>
  </id_info>
  <brief_title>Incretin Hormone Antagonism After Bariatric Surgery</brief_title>
  <acronym>INCA-BAR</acronym>
  <official_title>Importance of Endogenous Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide for Postprandial Glucose Metabolism After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using the glucagon-like peptide-1 (GLP-1) antagonist exendin(9-39) and the glucose-dependent
      insulinotropic peptide (GIP) antagonist GIP(3-30), the purpose of this study is to clarify
      the importance of endogenous GLP-1 and GIP for postprandial glucose metabolism after RYGB and
      SG in subjects with normal glucose tolerance. We hypothesize that GLP-1 is more important
      after RYGB, and GIP is more important after SG, for postprandial glucose tolerance and
      beta-cell function. A group of un-operated subjects with normal glucose tolerance will serve
      as controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iAUC glucose</measure>
    <time_frame>240 minutes</time_frame>
    <description>Main comparison between groups: delta iAUC glucose (iAUC exendin(9-39) test day - iAUC GIP(3-30) test day) in the RYGB group compared to the SG group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta-cell glucose sensitivity (β-GS)</measure>
    <time_frame>240 minutes</time_frame>
    <description>Main comparison between groups: delta β-GS (β-GS exendin(9-39) test day - β-GS GIP(3-30) test day) in the RYGB group compared to the SG group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>Gastric bypass operated patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four test days in a randomized, patient-blinded, cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleeve gastrectomy operated patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four test days in a randomized, patient-blinded cross-over, design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Un-operated controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four test days in a randomized, patient-blinded cross-over, design</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.</description>
    <arm_group_label>Gastric bypass operated patients</arm_group_label>
    <arm_group_label>Sleeve gastrectomy operated patients</arm_group_label>
    <arm_group_label>Un-operated controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-1 antagonism</intervention_name>
    <description>Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.</description>
    <arm_group_label>Gastric bypass operated patients</arm_group_label>
    <arm_group_label>Sleeve gastrectomy operated patients</arm_group_label>
    <arm_group_label>Un-operated controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP antagonism</intervention_name>
    <description>Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.</description>
    <arm_group_label>Gastric bypass operated patients</arm_group_label>
    <arm_group_label>Sleeve gastrectomy operated patients</arm_group_label>
    <arm_group_label>Un-operated controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-1 and GIP antagonism</intervention_name>
    <description>Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.</description>
    <arm_group_label>Gastric bypass operated patients</arm_group_label>
    <arm_group_label>Sleeve gastrectomy operated patients</arm_group_label>
    <arm_group_label>Un-operated controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria, surgery groups:

          -  Age &gt; 18 years

          -  RYGB or SG operation &gt; 12 months prior to inclusion

          -  Weight stable (± 3 kg during the last month)

          -  HbA1c &lt; 48 mmol/mol before surgery, and no history of diabetes

          -  HbA1c &lt; 48 mmol/mol and fasting plasma glucose &lt; 6.1 mmol/l at inclusion

        Inclusion Criteria, control group:

          -  Age &gt; 18 years

          -  no former RYGB- or SG operation

          -  Weight stable (± 3 kg during the last month)

          -  HbA1c &lt; 48 mmol/mol, fasting plasma glucose &lt; 6.1 mmol/l and no history of diabetes

        Exclusion Criteria:

          -  Thyrotoxicosis or inadequately treated hypothyreosis

          -  Hemoglobin &lt; 6.5 mmol/l at inclusion

          -  Pregnancy or breast feeding

          -  Medication affecting the planned examinations

        Matching between groups

          -  Age

          -  Sex

          -  BMI at inclusion and for surgery groups also pre-surgery BMI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirstine N Bojsen-Møller, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Endocrinology, Hvidovre Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morten G Hindsø, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Endocrinology, Hvidovre Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morten G Hindsø, MD</last_name>
    <phone>+45 38626371</phone>
    <email>morten.hindsoe@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kirstine N Bojsen-Møller, MD, PHD</last_name>
    <phone>+45 38626371</phone>
    <email>kirstine.nyvold.bojsen-moeller@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten G Hindsø, MD</last_name>
      <phone>+45 38626371</phone>
      <email>morten.hindsoe@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kirstine N Bojsen-Møller, MD, PHD</last_name>
      <phone>+45 38626371</phone>
      <email>kirstine.nyvold.bojsen-moeller@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Gadegaard Hindsø, MD</last_name>
      <phone>+45 38 62 63 71</phone>
      <email>morten.hindsoe@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Morten Gadegaard Hindsø, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>glucagon-like peptide-1</keyword>
  <keyword>glucose-dependent insulinotropic polypeptide</keyword>
  <keyword>Roux-en-Y gastric bypass</keyword>
  <keyword>sleeve gastrectomy</keyword>
  <keyword>gastric bypass</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>glucose</keyword>
  <keyword>diabetes</keyword>
  <keyword>exendin(9-39)</keyword>
  <keyword>GIP(3-30)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

